NYSEAM:NHC - Post by User
Comment by
DeltaVegaon Feb 08, 2017 2:52pm
377 Views
Post# 25818122
RE:Q4 Revenues Will Blow Through Guidance
RE:Q4 Revenues Will Blow Through GuidanceHF Show me the MONEY! Botton line and NOT Top.
TheRock077 wrote:
Full year 2016 total revenues are expected to be $281.0 million, and Adjusted EBITDA(1) is expected to be $53.0 million.
This implies $98 million in Q4 / 16 net sales and an adjusted Ebitda of $40 million.
In 2015, Q4 came in at $90 million and adjusted Ebitda of $22 million .
For the first 3 quarters of 2016, YOY quarterly revenue growth has been very steady at about 32%.
From what I know from other health care stock, Q4 of 2016 in the US was quite normal in its seasonal revenue gains.
In other words, 32% seems quite reasonable YOY revenue adjustment for Q4/16.
This implies a Q4 revenue of about $120 million plus a small amount of $4 million from the Arizona Vascular Clinic.
That is, Q4 /16 sales should exceed forecast estimate by at least $20 million.
Total sales for 2016 should hit $300 million vs $281 million estimate.
At this level of net sales, adjusted Ebitda for Q4 /16 should easily hit the $40 million level.